A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)

Journal of Neuro-Oncology

Volumn 86, Issue 3, 2008, Pages 353-358

  Swinnen, Lode J ^a   Rankin, Cathryn ^b   Carraway, Hetty ^a   Albain, Kathy S ^c   Townsend, Jeannette J ^d   Budd, George Thomas ^e   Kish, Julie A ^f   Rivkin, Saul E ^g   Blumenthal, Deborah T ^d,h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g USA   (United States)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cisplatin; DNA excision repair; Drug resistance; Glioma

Indexed keywords

CISPLATIN; CREATININE; CYTARABINE; HYDROXYUREA;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONVULSION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; HEARING LOSS; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RASH; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CISPLATIN; CYTARABINE; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 38049042414     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9483-3     Document Type: Article

References (26)

1. Albain KS, Swinnen LJ, Erickson LC, Stiff PJ, Fisher RI (1990) Cisplatin preceded by concurrent cytarabine and hydroxyurea: A pilot study based on an in vitro model. Cancer Chemother Pharmacol 27(1):33-40
2. Albain KS, Swinnen LJ, Erickson LC, Stiff PJ, Fisher SG, Fisher RI (1992) Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: Summary of an in vitro model and initial clinical pilot experience. Semin Oncol 19(3 Suppl 9):102-109
3. Beck DJ, Brubaker RR (1973) Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli. J Bacteriol 116(3):1247-1252
4. Dunn WC, Regan JD (1979) Inhibition of DNA excision repair in human cells by arabinofuranosyl cytosine: Effect on normal and xeroderma pigmentosum cells. Mol Pharmacol 15(2):367-374
5. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R, Eastern Cooperative Oncology Group (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol: Official J Am Soc Clin Oncol 21(8):1485-1491
6. Fram RJ, Cusick PS, Marinus MG (1986) Studies on mutagenesis and repair induced by platinum analogs. Mutat Res 173(1):13-18
7. Fram RJ, Kufe DW (1985) Effect of 1-beta-D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts. Biochem Pharmacol 34(14):2557-2560
8. Fraval HN, Rawlings CJ, Roberts JJ (1978) Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res 51(1):121-132
9. Hiss EA, Preston RJ (1977) The effect of cytosine arabinoside on the frequency of single-strand breaks in DNA of mammalian cells following irradiation or chemical treatment. Biochimica et Biophysica Acta 478(1):1-8
10. Konishi H, Usui T, Sawada H, Uchino H, Kidani Y (1981) Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity. Gann = Gan 72(4):627-630
11. Kufe DW, Weichselbaum R, Egan EM, Dahlberg W, Fram RJ (1984) Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Mol Pharmacol 25(2):322-326
12. Plooy AC, van Dijk M, Berends F, Lohman PH (1985) Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res 45(9):4178-4184
13. Poirier MC (1989) DNA adduct formation in tissues of human cancer patients. Proc Am Assoc Cancer Res 30(1):660-661
14. Reed E, Burt-Gupta S, Katz D, Poirier MC (1989) Platinum-DNA adducts measured at autposy in multiple human tissues. Proc Am Assoc Cancer Res 30:276
15. Shapiro WR (1986) Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13(1):38-45
16. Snyder RD (1984) The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea. Mutat Res 131(3-4):163-172
17. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS (1982) Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42(6):2474-2479
18. Stewart DJ, O'Bryan RM, Al-Sarraf M, Costanzi JJ, Oishi N (1983) Phase II study of cisplatin in recurrent astrocytomas in adults: A Southwest Oncology Group Study. J Neuro-Oncol 1(2):145-147
19. Stewart DJ, Richard MT, Benoit B, Hugenholtz H, Russell N, Dennery J, Peterson E, Grahovac Z, Belanger G, Aitkens S (1984) Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neuro-Oncol 2(1):29-34
20. Streifel JA, Howell SB (1981) Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine and hydroxyurea against human B cells and leukemic blasts in vitro. Proc Natl Acad Sci USA 78(8):5132-5136
21. Swinnen LJ, Barnes DM, Fisher SG, Albain KS, Fisher RI, Erickson LC (1989) 1-Beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res 49(6):1383-1389
22. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333-343
23. Walker RW, Allen JC (1988) Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol: Official J Am Soc Clin Oncol 6(1):62-66
24. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 303(23):1323-1329
25. Walsh CT, Craig RW, Agarwal RP (1980) Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Cancer Res 40(9):3286-3292
26. Warner HR, Demple BF, Deutsch WA, Kane CM, Linn S (1980) Apurinic/ apyrimidinic endonucleases in repair of pyrimidine dimers and other lesions in DNA. Proc Natl Acad Sci USA 77(8):4602-4606